Royalty Pharma plc(RPRX) Stock Research - Grey Stern Research
Loading...

Royalty Pharma plc (RPRX) Stock Analysis

$26.21 (-1.17%)

RPRX Financial Performance


Use the table below to view Royalty Pharma plc's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $26.21 -
52 Week Low $25.20 -
52 Week High $31.66 -
Market Cap $15.6 Billion 2/18
Gross Margin 99% 1/18
Profit Margin 19% 2/18
EBITDA margin 50% 2/18
Q2 - 2024 Revenue $537.3 Million 2/18
Q2 - 2024 Earnings $102.0 Million 1/18
Q2 - 2024 Free Cash Flow -$84.5 Million 11/18
Trailing 4 Quarters Revenue $2.2 Billion 2/18
Trailing 4 Quarters Earnings $673.2 Million 1/18
Quarterly Earnings Growth -55% 15/18
Annual Earnings Growth -46% 15/18
Quarterly Revenue Growth 0% 8/18
Annual Revenue Growth -14% 15/18
Cash On Hand $1.8 Billion 2/18
Short Term Debt $0 17/18
Long Term Debt $7.6 Billion 1/18

Royalty Pharma plc Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Royalty Pharma plc's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 23.10 1/18
PS 6.95 12/18
PB 1.60 11/18
PC 8.81 11/18
Liabilities to Equity 1.22 4/18
ROA 0.04 1/18
ROE 0.10 3/18
Current Ratio 2.23 12/18
Quick Ratio 0.23 17/18
Long Term Debt to Equity 1.17 1/18
Debt to Equity 1.17 2/18
Burn Rate 8.73 1/18
Cash to Cap 0.11 7/18
CCR -0.83 18/18
EV to EBITDA 79.34 1/18
EV to Revenue 9.56 10/18

Company Details

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

CEO: Mr. Pablo Gerardo Legorreta

Website: https://www.royaltypharma.com

Address: 110 East 59th Street New York, NY

Exchange: NASDAQ Global Select

Industry: Biotechnology

Royalty Pharma plc Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Royalty Pharma plc. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
BeiGene, Ltd. BGNE $23.0 Billion
Mirati Therapeutics, Inc. MRTX $4.1 Billion
Iovance Biotherapeutics, Inc. IOVA $3.2 Billion
Madrigal Pharmaceuticals, Inc. MDGL $7.6 Billion
Blueprint Medicines Corporation BPMC $6.4 Billion
Apellis Pharmaceuticals, Inc. APLS $3.7 Billion
Ascendis Pharma A/S ASND $7.1 Billion
Adaptive Biotechnologies Corporation ADPT $858.3 Million
IVERIC bio, Inc. ISEE $5.5 Billion
Karuna Therapeutics, Inc. KRTX $12.6 Billion
CureVac N.V. CVAC $637.0 Million
Kinnate Biopharma Inc. KNTE $125.0 Million
Ikena Oncology, Inc. IKNA $84.9 Million
Reneo Pharmaceuticals, Inc. RPHM $60.8 Million
Ocean Biomedical, Inc. OCEA $28.4 Million
Day One Biopharmaceuticals, Inc. DAWN $1.7 Billion
Ginkgo Bioworks Holdings, Inc. DNA $471.8 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RPRX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 537.3 Million $102.0 Million
Q1 2024 $ 568.0 Million $4.8 Million
Q4 2023 $ 596.0 Million $494.3 Million
Q3 2023 $ 536.3 Million $72.1 Million
Q2 2023 $ 538.2 Million $227.6 Million
Q1 2023 $ 684.0 Million $340.8 Million
Q4 2022 $ 565.7 Million -$610.2 Million
Q3 2022 $ 573.5 Million $142.7 Million

View All

RPRX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $1.8 Billion $17.7 Billion $7.6 Billion $9.8 Billion
Q1 2024 $843.0 Million $16.1 Billion $6.1 Billion $9.9 Billion
Q4 2023 $477.0 Million $16.4 Billion $6.1 Billion $10.1 Billion
Q3 2023 $936.4 Million $15.9 Billion $6.1 Billion $9.6 Billion
Q2 2023 $2.2 Billion $17.1 Billion $7.1 Billion $6.3 Billion
Q1 2023 $2.0 Billion $17.1 Billion $7.1 Billion $6.0 Billion
Q4 2022 $1.7 Billion $16.8 Billion $7.1 Billion $5.6 Billion
Q3 2022 $991.6 Million $17.7 Billion $7.1 Billion $10.4 Billion

View All

RPRX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$84.5 Million -$746.6 Million $921.6 Million
Q1 2024 $583.5 Million -$86.1 Million $366.0 Million
Q4 2023 -$225.0 Million -$1.0 Billion -$459.4 Million
Q3 2023 $573.5 Million $0 -$1.2 Billion
Q2 2023 $607.8 Million $0 $197.4 Million
Q1 2023 $1.0 Billion $0 $264.9 Million
Q4 2022 $569.9 Million $0 $719.1 Million
Q3 2022 $538.8 Million $0 -$1.1 Billion

View All